CDXC - クロマデックス （ChromaDex Corporation）

ChromaDex (NASDAQ: CDXC ) is set to give its latest quarterly earnings report on Wednesday, 2023-03-08. Here''s what investors need to know before the announcement. Analysts estimate that ChromaDex will report an earnings per share (EPS) of $-0.02. ChromaDex bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call o

https://www.investing.com/news/assorted/chromadex-announces-letter-from-the-chief-executive-officer-432SI-3009136

The following is issued on behalf of ChromaDex (NASDAQ: CDXC). Dear Fellow Shareholders: I want to take this opportunity to provide an update on ChromaDex’s intellectual property portfolio, as well as perspective on why our business is not impacted by a recent court decision related to one of the Dartmouth patents slated to expire in 2026. Last week we learned that the U.S. Court of

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising findings from a first-of-its kind five-month-long clinical study, as reported in the peer-reviewed journal Science Advances by a team of scientists led by Dr. Eija Pirinen (University of Helsinki and University of Oulu) and Dr. Kirsi Pietiläinen (University of Helsinki). The clinical

ChromaDex shares are down more than 80% since February 2021 as momentum for its flagship Tru Niagen product stalled. Read what''s next for this dietary supplement concern.

ChromaDex Corporation (NASDAQ:CDXC) price is hovering lower on Tuesday, November 08, dropping -12.50% below its previous close. A look at today’s price movement shows that the recent level at last check reads $2.16, with intraday deals fluctuating between $1.88 and $2.16. The company’s 5Y monthly beta was ticking 1.77. Taking into account the 52-week price … ChromaDex Corporation (NASDAQ: CDXC) Is One Of The Hottest Stocks Right Now. Read More »

In last trading session, ChromaDex Corporation (NASDAQ:CDXC) saw 0.64 million shares changing hands with its beta currently measuring 1.76. Company’s recent per share price level of $1.90 trading at $0.2 or 11.76% at ring of the bell on the day assigns it a market valuation of $141.83M. That closing price of CDXC’s stock is at … ChromaDex Corporation (NASDAQ:CDXC) Has Recovered -69.55% To Date, But An Additional -243.68% Is Possible. Read More »

As of Thursday, ChromaDex Corporation’s (NASDAQ:CDXC) stock closed at $1.70, up from $1.67 the previous day. While ChromaDex Corporation has overperformed by 1.80%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CDXC fell by -74.05%, with highs and lows ranging from $6.57 to $1.15, whereas the […]

ChromaDex Corporation (NASDAQ:NASDAQ:CDXC) Q3 2022 Earnings Conference Call November 2, 2022 16:30 ET Company Participants Tom Shumaker - Investor Relations Robert Fried - Chief Executive…

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. August 10, 2022 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2022. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the second quarter re

In last trading session, ChromaDex Corporation (NASDAQ:CDXC) saw 0.31 million shares changing hands with its beta currently measuring 1.77. Company’s recent per share price level of $1.91 trading at -$0.1 or -4.98% at ring of the bell on the day assigns it a market valuation of $129.75M. That closing price of CDXC’s stock is at … ChromaDex Corporation (NASDAQ:CDXC) Stock Dropped -48.93% Year-To-Date, What Analysts Expect Next? Read More »

ChromaDex Corporation (NASDAQ:CDXC) traded at $1.92 at last check on Wednesday, July 20, made an upward move of 13.51% on its previous day’s price. Looking at the stock we see that its previous close was $1.69 and the beta (5Y monthly) reads 1.77 with the day’s price range being $1.68 – $1.77. In terms of … Is ChromaDex Corporation (NASDAQ: CDXC) Stock Good For Medium-Term Investing? Read More »

Life sciences company ChromaDex Corporation (CDXC) announced an agreement with Sinopharm Xingsha, the health supplement division of Sinopharm Group (SHTDF) (SHTDY) on Friday to speed…

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced a signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of Tru Niagen into mainland China. Tru Niagen features ChromaDex’s proprietary Niagen (patented nicotinamide riboside or NR) ingredient, which is the world’s most efficient NAD+ (nicotinamide